# Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

> **NCT00442507** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 6 (actual)

## Conditions studied

- Esophageal Neoplasms
- Esophageal Diseases

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT00442507
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2015-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442507, "Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00442507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*